

**OPIOID OVERDOSAGE AND HARM REDUCTION STRATEGIES IN LOWER-INCOME COUNTRIES: A COMPREHENSIVE REVIEW**

Zahra Zahid Piracha<sup>\*1</sup>, Umar Saeed<sup>2</sup>, Amal Sohail Malik<sup>3</sup>, Muhammad Nouman Tariq<sup>4</sup>, Syed Shayan Gilani<sup>4</sup>, Laiba Razaq<sup>4</sup>, Manaal Amir Basra<sup>5</sup>, Talha Abdul Waheed<sup>6</sup>, Ayesha Israr<sup>7</sup>, Seneen Noor<sup>8</sup> and Elyeen Noor<sup>9</sup>

<sup>1</sup>International Center of Medical Sciences Research – ICMSR, Islamabad, Pakistan.

<sup>2</sup>Foundation University Islamabad Pakistan, Foundation University School of Health Sciences, Clinical and Biomedical Research Center, Islamabad, Pakistan.

<sup>3</sup>Central Park Teaching Hospital, Lahore.

<sup>4</sup>Akhtar Saeed Medical & Dental College Lahore.

<sup>5</sup>Rahbar Medical & Dental College Lahore.

<sup>6</sup>Frontier Medical College Abbotabad, Pakistan.

<sup>7</sup>Rawalpindi Medical University Rawalpindi.

<sup>8</sup>International Center of Medical Sciences Research – ICMSR, Austin, TX, United States of America.

<sup>9</sup>International Center of Medical Sciences Research – ICMSR, Chadwell Health, United Kingdom.



\*Corresponding Author: Zahra Zahid Piracha

International Center of Medical Sciences Research – ICMSR, Islamabad, Pakistan.

Article Received on 09/04/2024

Article Revised on 30/04/2024

Article Accepted on 21/05/2024

**ABSTRACT**

**Background:** Opioid receptor agonists, encompassing substances like heroin and prescription opioids, pose a pronounced public health challenge globally. Non-fatal opioid overdoses, especially prevalent among prescription opioid users, exceed fatal cases. The effectiveness of Take-Home Naloxone (THN) programs, proven in higher-income nations, remains uncertain in lower-income countries. **Objectives:** This study aims to comprehensively analyze review articles addressing opioid overdose and harm reduction strategies, with a specific focus on resource-constrained settings. Objectives include identifying prevalent risk factors, evaluating the effectiveness of harm reduction measures, and formulating a practical change plan for implementing THN strategies in developing nations. **Methods:** A meticulous search across Medline/PubMed, Science Direct, PsycINFO, Google Scholar, and the Virginia Commonwealth University library facilitated the identification of relevant review articles. Keywords such as "Naloxone," "take-home naloxone," and "opioid overdose prevention" were strategically employed. Data extraction emphasized overdose prevalence, contributing factors, and harm reduction efficacy. Thematic analysis categorized data into interventions, socio-economic factors, risk factors, and harm reduction strategies. **Results:** Findings underscore the urgency of tailored harm reduction strategies in lower-income countries, recognizing regional disparities, cultural influences, and healthcare infrastructure variations. THN emerges as a critical intervention, but its implementation requires nuanced approaches. Challenges include limited healthcare resources, stigma, and cultural factors influencing opioid use patterns. **Conclusion:** This study provides insights into the socio-economic determinants of opioid overdose and existing harm reduction strategies, laying the groundwork for future efforts. Tailored interventions, encompassing drug safety testing, supply management, injectable opioid programs, pain management, policy solutions, and stigma reduction, are crucial in addressing opioid-related challenges in resource-limited contexts. The findings guide a practical change plan for THN implementation in developing nations.

**KEYWORDS:** Keywords such as "Naloxone," "take-home naloxone," and "opioid overdose prevention" were strategically employed.

**INTRODUCTION**

The escalating global prevalence of opioid misuse and its associated consequences have positioned opioid overdosage as a formidable public health challenge. Opioid receptor agonists, encompassing substances such as heroin and prescription opioids like oxycodone, hydrocodone, codeine, fentanyl, and morphine,

contribute significantly to the rising burden of morbidity and mortality. The intricate interplay of risk factors, including high doses, male gender, and concurrent use of depressogenic medications, underscores the complexity of addressing non-fatal opioid overdoses, which currently outnumber fatal cases.<sup>[1]</sup>

Despite the growing awareness of opioid-related risks, the predicament intensifies for lower-income countries. Prescription opioid misuse, often driven by factors such as limited healthcare resources, lack of stringent regulations, and socio-economic challenges, adds a layer of complexity to an already multifaceted issue. In these resource-constrained settings, the prevalence of non-fatal overdoses is exacerbated, creating a pressing need for tailored harm reduction strategies.<sup>[2]</sup>

An alarming aspect of opioid overdosage is the heightened risk associated with a history of previous overdoses. This alarming trajectory underscores the urgency to explore and implement effective harm reduction strategies in diverse global contexts, especially those grappling with economic constraints. While community-based programs, exemplified by the success of Take-Home Naloxone (THN) initiatives in North America, Europe, and Australia, have demonstrated efficacy, their applicability in lower-income countries remains uncertain.<sup>[3,4]</sup> Understanding the distinct challenges faced by these regions is pivotal for formulating nuanced interventions.

This report endeavors to provide a comprehensive analysis of review articles focusing on opioid overdoses in lower-income countries and the imperative implementation of harm reduction strategies. Beyond a mere enumeration of challenges, this exploration delves into the nuanced landscape of drug safety testing, supply chain management, injectable opioid programs, pain management strategies, policy interventions, and the reduction of societal stigma surrounding opioid use. Recognizing that a one-size-fits-all approach is untenable, the research aims to unveil a multifaceted framework that addresses the intricacies of opioid-related issues in resource-constrained settings.

Crucially, the overarching objective is not only to delineate the challenges but also to illuminate a path forward. By deciphering the unique contours of opioid-related concerns in lower-income countries, this research aspires to inform an effective and practical change plan. The focus on the implementation of Take-Home Naloxone (THN) strategies specifically caters to the need for context-specific interventions in developing countries. Through a judicious amalgamation of global insights and locally relevant solutions, the research aims to contribute to the advancement of strategies that can be feasibly integrated into the complex socio-economic and healthcare landscapes of lower-income countries.

### Study Design and Methodology

To conduct a comprehensive review of the literature on opioid overdosage and harm reduction strategies in lower-income countries, a meticulous study design and methodology were employed. The search strategy utilized multiple databases, including Medline/PubMed, Science Direct, PsycINFO, and Google Scholar, to ensure a thorough exploration of the existing literature.

The search incorporated a range of keywords, such as (Naloxone), (take-home naloxone), (naloxone kits), (low-income countries), (middle-income countries), (poor countries), (developed countries), (developing countries), (Naloxone barriers), and (opioid overdose prevention) in various combinations. MeSH terms related to drug overdose, drug therapy, epidemiology, prescription drugs, and narcotic antagonists were also utilized. The inclusion of specific country names and additional keywords like "harm reduction" and "opioid overdose" aimed to narrow the focus on lower-income countries. Naloxone emerged as a pivotal preventive measure with an excellent safety profile and effectiveness in countering opioid overdosage. The take-home naloxone (THN) strategy, including pre-filled syringes, auto-injectors, and concentrated intranasal naloxone sprays, was highlighted for its potential to be pre-provided to individuals capable of intervening in overdose situations. The S-O-S initiative set ambitious global targets (90-90-90) for overdose risk and emergency management training, naloxone supply, and naloxone carrying or accessibility.<sup>[5,6]</sup>

### Socioeconomic Factors Related to Opioid Overdosage

A global survey conducted after the COVID-19 pandemic declaration highlighted the impact on substance use disorder (SUD) treatment and harm reduction services. Shortages of methadone or buprenorphine supplies, discontinuation of harm reduction services, and significant disruptions in overdose prevention and outreach services were reported, emphasizing the need for effective strategies during health crises.<sup>[7]</sup> Another research, through qualitative interviews, identified challenges and strategies for implementing harm reduction services in non-urban areas (8). The study included all types of opioid users, family members, peers, significant others, and laypersons related to opioid users. Exclusion criteria considered geographic scope, cultural sensitivity, data availability, legal and regulatory differences, language barriers, infrastructure limitations, and political instability or conflict.<sup>[1,2]</sup>

### Types of Opioids Used Globally

#### Heroin

Heroin, derived from morphine, is a highly addictive illegal opioid. Its use is prevalent in many parts of the world, particularly in urban areas. Heroin can be injected, smoked, or snorted, contributing to its widespread misuse.<sup>[9,10]</sup>

#### Prescription Opioids

Prescription opioids, including oxycodone, hydrocodone, codeine, fentanyl, and morphine, are legal medications commonly used for pain management. However, misuse, overprescription, and diversion for non-medical purposes contribute to opioid-related issues globally.<sup>[11]</sup>

### Synthetic Opioids

Fentanyl and its analogs are synthetic opioids that are much more potent than traditional opioids. They are associated with a significant risk of overdose due to their potency. Illicitly manufactured fentanyl has been implicated in numerous overdose deaths, particularly in North America.<sup>[12]</sup>

### Opium

Opium, obtained from the poppy plant, has been used for centuries for medicinal and recreational purposes. In some regions, opium use is deeply ingrained in cultural practices, but its misuse can lead to dependence and other health issues.<sup>[13]</sup>

### Global Opioid Usage Trends

North America has faced a well-documented opioid epidemic, initially driven by the overprescription of pain medications. The crisis evolved with the influx of illicit opioids like fentanyl, leading to a surge in overdose deaths. European countries exhibit diverse opioid use patterns. Some face challenges related to heroin use, while others contend with prescription opioid misuse. Harm reduction measures, such as supervised consumption sites, are implemented in various European nations. Asia has a history of opium use, with variations in opioid consumption across countries. In some regions, such as the Golden Triangle, heroin production and use have been prevalent. Synthetic opioids also pose emerging threats in certain areas. Opioid misuse in Africa is generally lower compared to other continents. However, challenges still exist, particularly in regions where heroin trafficking routes pass through. Limited data availability makes it challenging to estimate precise prevalence rates.<sup>[14]</sup>

### Middle-Income Countries and Opioid Usage

Middle-income countries exhibit diverse opioid usage patterns influenced by socio-economic factors and cultural influences. The prevalence of heroin and prescription opioid misuse varies widely, with rapidly growing economies potentially facing challenges associated with increased opioid consumption. Some middle-income countries may also encounter issues related to the trafficking and misuse of synthetic opioids. Access to evidence-based treatment, including medication-assisted treatment, may be more available compared to low-income countries. Efforts to enhance treatment accessibility and harm reduction strategies are crucial in mitigating the impact of opioid misuse in these diverse regions.<sup>[15]</sup>

### Opioid in High-Income Countries

In high-income countries, prescription opioid use has been a significant concern, contributing to both medical and non-medical opioid usage. The prevalence of medical prescriptions for opioids, such as oxycodone and hydrocodone, has been notable, particularly for managing chronic pain conditions. The opioid overdose epidemic, initially fueled by the overprescription of

opioid pain medications, has been particularly prominent in some high-income regions, notably in North America. In the United States, for instance, there has been a documented opioid crisis characterized by high rates of opioid prescriptions, opioid-related deaths, and an increase in the misuse of prescription opioids and illicit substances like heroin. The prevalence of opioid use disorders and overdose deaths has led to concerted efforts to implement harm reduction strategies, expand access to naloxone, and improve treatment options. In countries like Canada, Australia, and several European nations, while prescription opioid misuse has also been a concern, harm reduction measures and treatment accessibility have been integral components of the response. Take-Home Naloxone (THN) programs, supervised consumption sites, and medication-assisted treatment (MAT) have been implemented to address the multifaceted challenges associated with opioid misuse. It's crucial to note that prevalence data can vary widely among high-income countries due to differences in healthcare systems, prescribing practices, cultural attitudes toward pain management, and regulatory frameworks. Additionally, responses to the opioid epidemic have evolved over time, with increased awareness and initiatives to curb overprescription, enhance monitoring, and improve access to treatment services. For the most current and specific prevalence data, consulting recent reports and publications from public health agencies and research institutions is recommended.<sup>[14-17]</sup>

### Challenges in Low-Income Countries

Low-income countries often lack the infrastructure and funding for comprehensive data collection, treatment facilities, and harm reduction programs. Stigma surrounding drug use can lead to underreporting of opioid-related issues, hindering accurate assessments of prevalence and the extent of the problem. Access to evidence-based treatment for opioid use disorders may be limited in many low-income countries. This lack of resources exacerbates the challenges of addressing opioid-related issues.<sup>[14-17]</sup>

### Prevalence of Opioid Usage in Selected Low-Income Countries

#### Sub-Saharan Africa

Opioid use is generally lower, but pockets of heroin and prescription opioid misuse exist. Reliable prevalence data is limited due to insufficient research and reporting. Sub-Saharan Africa generally experiences lower levels of opioid usage compared to other regions. While there are pockets of heroin use, often linked to trafficking routes passing through the continent, the prevalence remains limited. Countries along the East African coast, such as Kenya and Tanzania, are reported transit points for heroin trafficking. The use of prescription opioids is not as widespread, and regulatory measures may limit access. Challenges include a lack of comprehensive research and reporting, leading to underreporting due to stigma and limited resources. This scarcity of data

hinders a detailed understanding of opioid usage patterns in the region.<sup>[18, 19]</sup>

### South Asia

Opium has historical significance in some South Asian countries, and issues related to heroin use are present. However, prevalence rates can vary, and data may be sparse. South Asia has a historical association with opium use, with cultural and traditional significance in some communities. Afghanistan, a major global producer of opium, contributes significantly to the region's dynamics. Heroin use poses challenges in countries like Pakistan and India, where production and trafficking are significant concerns. Varied prevalence of prescription opioid misuse exists across countries, with India reporting issues related to overprescription and misuse of opioid pain medications. Challenges in the region include high levels of poverty, limited healthcare resources, and insufficient data collection, impacting the ability to address opioid-related issues effectively.<sup>[14, 15, 20]</sup>

### Southeast Asia

The Golden Triangle region has a history of opium cultivation, leading to challenges related to heroin production and use. The prevalence of opioid use varies across countries. The Golden Triangle region, comprising Myanmar, Laos, and Thailand, has a historical connection with opium cultivation. Heroin production and trafficking have been prevalent in this area. Countries like Myanmar face challenges associated with heroin use, while emerging concerns focus on synthetic opioids, including fentanyl analogs. Ongoing issues related to poverty, political instability, and limited healthcare infrastructure impact efforts to address opioid misuse effectively. Regional variations in drug use patterns further complicate the development of uniform interventions in Southeast Asia.<sup>[14, 15, 20]</sup>

### Latin America

Certain Latin American countries, particularly in Central America, experience issues related to opioid misuse. The prevalence is influenced by factors such as drug trafficking routes and local drug consumption patterns. Certain countries in Latin America, particularly in Central America, experience issues related to heroin misuse. Mexico, a key transit and illicit drug-producing country, contributes to the availability of opioids in the region. Limited documented cases of widespread prescription opioid misuse exist, and the availability of prescription opioids may vary across countries. Additionally, some Andean countries like Peru and Bolivia may use coca-derived opioids traditionally. Challenges in Latin America include drug trafficking routes, socio-economic issues, and limited healthcare resources, which collectively impact efforts to address opioid misuse effectively.<sup>[14, 21, 22]</sup>

### Efforts and Interventions

Harm Reduction Programs: Implementation of harm reduction strategies, including naloxone distribution, needle exchange programs, and supervised consumption sites, can mitigate the adverse effects of opioid misuse.<sup>[23]</sup>

### Treatment Access

Improving access to evidence-based treatment options, such as medication-assisted treatment with methadone or buprenorphine, is critical for addressing opioid use disorders and promoting recovery. The complex landscape of opioid usage involves diverse substances, trends, and challenges. Tailored interventions, taking into account cultural, economic, and regional variations, are essential to effectively address opioid-related issues globally.<sup>[14, 24]</sup>

### REFERENCES

1. Greer, A., & Ritter, A. (2019). Harm reduction and the opioid crisis: emerging policy challenges. *International Journal of Drug Policy*, 71: 139-141.
2. Wakeman, S. E. (2019). Harm reduction approaches for opioid use disorder. In J. Kelly & S. Wakeman (Eds.), *Treating Opioid Addiction* (pp. 8). Humana.
3. Sajwani, H. S., & Williams, A. V. (2022). A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs. *Harm Reduction Journal*, 19(1): 117.
4. McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. *Addiction*, 111(7): 1177-1187.
5. Strang, J., McDonald, R., Campbell, G., Degenhardt, L., Nielsen, S., Ritter, A., & Dale, O. (2019). Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. *Drugs*, 79: 1395-1418.
6. UNODC-WHO. (2021). UNODC-WHO Stop-Overdose-Safely (S-O-S) Project Implementation in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine: Summary Report. WHO/UNODC. Accessed January 31: 2024.
7. Radfar, S. R., De Jong, C. A., Farhoudian, A., Ebrahimi, M., Rafei, P., Vahidi, M., ... & Deylamizadeh, A. (2021). Reorganization of substance use treatment and harm reduction services during the COVID-19 pandemic: a global survey. *Frontiers in Psychiatry*, 12: 639393.
8. Childs, E., Biello, K. B., Valente, P. K., Salhaney, P., Biancarelli, D. L., Olson, J., ... & Bazzi, A. R. (2021). Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: a qualitative study exploring challenges and mitigating strategies. *International Journal of Drug Policy*, 90: 103080.

9. Sweetman, S. C. (Ed.). (2009). *Martindale: The Complete Drug Reference* (36th ed.). London: Pharmaceutical Press, p. 42.
10. Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. *Morbidity and Mortality Weekly Report*, 65: 1445–1452.
11. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. *MMWR Recomm Rep*, 65(No. RR-1), 1–49.
12. WHO. (2019). *International Classification of Diseases for Mortality and Morbidity Statistics, Eleventh Revision*.
13. Merlin, M. D. (2003). "Archaeological Evidence for the Tradition of Psychoactive Plant Use in the Old World". *Economic Botany*, 57(3): 295–323.
14. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse; Phillips JK, Ford MA, Bonnie RJ, editors. *Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use*. Washington (DC): National Academies Press (US); 2017 Jul 13. 4, Trends in Opioid Use, Harms, and Treatment. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK458661/>
15. Jalali, M. S., Botticelli, M., Hwang, R. C., & et al. (2020). The opioid crisis: a contextual, social-ecological framework. *Health Research Policy and Systems*, 18: 87.
16. Schmidt, L., Finnerty Mutlu, A. N., Elmore, R., Olorisade, B. K., Thomas, J., & Higgins, J. P. T. (2021). Data extraction methods for systematic review (semi)automation: Update of a living systematic review. *F1000Research*, 10: 401.
17. Hawk, K. F., Vaca, F. E., & D'Onofrio, G. (2015). Reducing fatal opioid overdose: prevention, treatment, and harm reduction strategies. *The Yale Journal of Biology and Medicine*, 88(3): 235.
18. Kurth, A. E., Cherutich, P., Conover, R., Chhun, N., Bruce, R. D., & Lambdin, B. H. (2018). The Opioid Epidemic in Africa And Its Impact. *Current Addiction Reports*, 5(4): 428-453.
19. Sabogal de la Pava, M. L., & Tucker, E. L. (2022). Drug shortages in low- and middle-income countries: Colombia as a case study. *Journal of Pharmaceutical Policy and Practice*, 15: 42.
20. Suwanwela, C., & Poshyachinda, V. (1986). Drug abuse in Asia. *Bulletin on Narcotics*, 38(1-2), 41-53. PMID: 3535959.
21. Goodman-Meza, D., Medina-Mora, M. E., Magis-Rodríguez, C., Landovitz, R. J., Shoptaw, S., & Werb, D. (2019). Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border. *American Journal of Public Health*, 109(1): 73-82.
22. Van Draanen, J., Tsang, C., Mitra, S., Karamouzian, M., & Richardson, L. (2020). Socioeconomic marginalization and opioid-related overdose: a systematic review. *Drug and Alcohol Dependence*, 214: 108127.
23. Thakarar, K., Nenninger, K., & Agmas, W. (2020). Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs. *Infectious Disease Clinics of North America*, 34(3): 605-620.
24. Flores, L., & Young, S. D. (2021). Regional variation in discussion of opioids on social media. *Journal of Addictive Diseases*, 39(3): 316-321.